bluuebunny/crossref_metadata_2025 huggingface dataset:
Figure S1 from COX-2/sEH Dual Inhibitor PTUPB Potentiates the Antitumor Efficacy of Cisplatin
Authors: Wang Fuli , Zhang Hongyong , Ma Ai-Hong , Yu Weimin , Zimmermann Maike , Yang Jun , Hwang Sung Hee , Zhu Daniel , Lin Tzu-yin , Malfatti Michael , Turteltaub Kenneth W. , Henderson Paul T. , Airhart Susan , Hammock Bruce D. , Yuan Jianlin , de Vere White Ralph W. , Pan Chong-Xian
Published: April 2023

PTUPB structure
Table S1 from Impact of the Anticancer Drug NT157 on Tyrosine Kinase Signaling Networks
Authors: Su Shih-Ping , Flashner-Abramson Efrat , Klein Shoshana , Gal Mor , Lee Rachel S. , Wu Jianmin , Levitzki Alexander , Daly Roger J.
Published: April 2023

Summary of phosphoproteomic profiling data.
Supplementary Figure Legends from Impact of the Anticancer Drug NT157 on Tyrosine Kinase Signaling Networks
Authors: Su Shih-Ping , Flashner-Abramson Efrat , Klein Shoshana , Gal Mor , Lee Rachel S. , Wu Jianmin , Levitzki Alexander , Daly Roger J.
Published: April 2023

Supplementary Figure Legends
Figure S7 from Impact of the Anticancer Drug NT157 on Tyrosine Kinase Signaling Networks
Authors: Su Shih-Ping , Flashner-Abramson Efrat , Klein Shoshana , Gal Mor , Lee Rachel S. , Wu Jianmin , Levitzki Alexander , Daly Roger J.
Published: April 2023

Protein-protein interaction (A) and pathway analysis (B) for sites exhibiting delayed induction upon NT157 treatment (Cluster 3).
Figure S4 from Impact of the Anticancer Drug NT157 on Tyrosine Kinase Signaling Networks
Authors: Su Shih-Ping , Flashner-Abramson Efrat , Klein Shoshana , Gal Mor , Lee Rachel S. , Wu Jianmin , Levitzki Alexander , Daly Roger J.
Published: April 2023

Heatmap for Cluster 5.
Figure S2 from Impact of the Anticancer Drug NT157 on Tyrosine Kinase Signaling Networks
Authors: Su Shih-Ping , Flashner-Abramson Efrat , Klein Shoshana , Gal Mor , Lee Rachel S. , Wu Jianmin , Levitzki Alexander , Daly Roger J.
Published: April 2023

Heatmap for Cluster 1.
Table S4 from JQ1 Induces DNA Damage and Apoptosis, and Inhibits Tumor Growth in a Patient-Derived Xenograft Model of Cholangiocarcinoma
Authors: Garcia Patrick L. , Miller Aubrey L. , Gamblin Tracy L. , Council Leona N. , Christein John D. , Arnoletti J. Pablo , Heslin Marty J. , Reddy Sushanth , Richardson Joseph H. , Cui Xiangqin , van Waardenburg Robert C.A.M. , Bradner James E. , Yang Eddy S. , Yoon Karina J.
Published: April 2023

Expression Indices
Supplementary Table 1 from EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer
Authors: Martini Giulia , Cardone Claudia , Vitiello Pietro Paolo , Belli Valentina , Napolitano Stefania , Troiani Teresa , Ciardiello Davide , Della Corte Carminia Maria , Morgillo Floriana , Matrone Nunzia , Sforza Vincenzo , Papaccio Gianpaolo , Desiderio Vincenzo , Paul Mariel C. , Moreno-Viedma Veronica , Normanno Nicola , Rachiglio Anna Maria , Tirino Virginia , Maiello Evaristo , Latiano Tiziana Pia , Rizzi Daniele , Signoriello Giuseppe , Sibilia Maria , Ciardiello Fortunato , Martinelli Erika
Published: April 2023

Supplementary Table 1: Treatment with ALW-II-41-27 or cetuximab as single agents
Supplementary Figure 1 from EPHA2 Is a Predictive Biomarker of Resistance and a Potential Therapeutic Target for Improving Antiepidermal Growth Factor Receptor Therapy in Colorectal Cancer
Authors: Martini Giulia , Cardone Claudia , Vitiello Pietro Paolo , Belli Valentina , Napolitano Stefania , Troiani Teresa , Ciardiello Davide , Della Corte Carminia Maria , Morgillo Floriana , Matrone Nunzia , Sforza Vincenzo , Papaccio Gianpaolo , Desiderio Vincenzo , Paul Mariel C. , Moreno-Viedma Veronica , Normanno Nicola , Rachiglio Anna Maria , Tirino Virginia , Maiello Evaristo , Latiano Tiziana Pia , Rizzi Daniele , Signoriello Giuseppe , Sibilia Maria , Ciardiello Fortunato , Martinelli Erika
Published: April 2023

Supplementary Figure 1. A: Phosphoarray analysis of SW48 and SW48-CR cell lines. B: Silencing of EPHA2 decreases the sensitivity to ALW-II-41-27 in HCT15 and SW48-CR cell lines.
Video 2 from Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia
Authors: Buatois Vanessa , Johnson Zoë , Salgado-Pires Susana , Papaioannou Anne , Hatterer Eric , Chauchet Xavier , Richard Françoise , Barba Leticia , Daubeuf Bruno , Cons Laura , Broyer Lucile , D'Asaro Matilde , Matthes Thomas , LeGallou Simon , Fest Thierry , Tarte Karin , Clarke Hinojosa Robert K. , Genescà Ferrer Eulàlia , Ribera José María , Dey Aditi , Bailey Katharine , Fielding Adele K. , Eissenberg Linda , Ritchey Julie , Rettig Michael , DiPersio John F. , Kosco-Vilbois Marie H. , Masternak Krzysztof , Fischer Nicolas , Shang Limin , Ferlin Walter G.
Published: April 2023

Video 2 shows the real time phagocytosis of cancer cells in presence of hIgG1 control
Video 1 from Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia
Authors: Buatois Vanessa , Johnson Zoë , Salgado-Pires Susana , Papaioannou Anne , Hatterer Eric , Chauchet Xavier , Richard Françoise , Barba Leticia , Daubeuf Bruno , Cons Laura , Broyer Lucile , D'Asaro Matilde , Matthes Thomas , LeGallou Simon , Fest Thierry , Tarte Karin , Clarke Hinojosa Robert K. , Genescà Ferrer Eulàlia , Ribera José María , Dey Aditi , Bailey Katharine , Fielding Adele K. , Eissenberg Linda , Ritchey Julie , Rettig Michael , DiPersio John F. , Kosco-Vilbois Marie H. , Masternak Krzysztof , Fischer Nicolas , Shang Limin , Ferlin Walter G.
Published: April 2023

Video 1 shows the real time phagocytosis of cancer cells in presence of NI-1701
Supplementary Figures S1-S8 from G-1 Inhibits Breast Cancer Cell Growth via Targeting Colchicine-Binding Site of Tubulin to Interfere with Microtubule Assembly
Authors: Lv Xiangmin , He Chunbo , Huang Cong , Hua Guohua , Wang Zhengfeng , Remmenga Steven W. , Rodabough Kerry J. , Karpf Adam R. , Dong Jixin , Davis John S. , Wang Cheng
Published: April 2023

Supplementary Figure S1. G-1 suppresses breast cancer cell proliferation regardless of expression status of GPER and classic estrogen receptors. Supplementary Figure S2. G-1 inhibits proliferation of triple negative breast cancer (TNBC) cells in a GPER independent manner. Supplementary Figure S3. G-1 Induced Caspase activation and Apoptosis of breast cancer cells. Supplementary Figure S4. Effects of G-1 treatment on the cell cycle progression of breast cancer cells. Supplementary Figure S5. G-1 arrests cell cycle in the prophase of mitosis in breast cancer cells regardless of GPER expression. Supplementary Figure S6. Effects of G-1 on the cell cycle progression in three breast cancer cell lines examined by fluorescent immunocytochmemistry. Supplementary Figure S7. Comparison of the effects of G-1 and known microtubule targeting agents on the morphology and cell cycle progression of breast cancer cells. Supplementary Figure S8. G-1 disrupts cellular microtubule network in a concentration-dependent manner.
Supplementary Figure S1 from Preclinical Development of a Bispecific Antibody that Safely and Effectively Targets CD19 and CD47 for the Treatment of B-Cell Lymphoma and Leukemia
Authors: Buatois Vanessa , Johnson Zoë , Salgado-Pires Susana , Papaioannou Anne , Hatterer Eric , Chauchet Xavier , Richard Françoise , Barba Leticia , Daubeuf Bruno , Cons Laura , Broyer Lucile , D'Asaro Matilde , Matthes Thomas , LeGallou Simon , Fest Thierry , Tarte Karin , Clarke Hinojosa Robert K. , Genescà Ferrer Eulàlia , Ribera José María , Dey Aditi , Bailey Katharine , Fielding Adele K. , Eissenberg Linda , Ritchey Julie , Rettig Michael , DiPersio John F. , Kosco-Vilbois Marie H. , Masternak Krzysztof , Fischer Nicolas , Shang Limin , Ferlin Walter G.
Published: April 2023

Supplementary Figure S1 shows shows the percentage of in vitro phagocytosis of Raji cells by macrophages with NI-1701 or CD19/CD47hi biAb.
Supplementery Materials and Methods from p110α Inhibition Overcomes Stromal Cell–Mediated Ibrutinib Resistance in Mantle Cell Lymphoma
Authors: Guan Jiyu , Huang Dan , Yakimchuk Konstantin , Okret Sam
Published: April 2023

Supplementary Materials and Methods
Supplemental Figures 1-12 from Ceritinib Enhances the Efficacy of Trametinib in BRAF/NRAS-Wild-Type Melanoma Cell Lines
Authors: Verduzco Daniel , Kuenzi Brent M. , Kinose Fumi , Sondak Vernon K. , Eroglu Zeynep , Rix Uwe , Smalley Keiran S.M.
Published: April 2023

File containing 12 Supplemental Figures. Figure 1 shows a kinome array on WM209 cells, Figure 2 shows detail from the kinome array. Figure 3 shows the effects of the drugs upon p-c-JUN in the BRAF/NRAS WT cell lines. Figure 4 is a time course of pS6 and pERK inhibition following drug treatment. Figure 5 is the effects of drug upon SPRY-2. Figure 6 shows the structure of c-ceritinib. Figure 7 is the IGF1R expression in the cell line panel. Figure 8 is an RTK array following ceritinib treatment. Figure 9 is the effects of IGF1R siRNA upon cell growth. Figure 10 shows the effects of ceritinib and trametinib upon FAK expression. Figure 11 shows the effects of FER silencing upon the growth of the melanoma cells. Figure 12 is the effects of an ACK1 inhibitor and a MEK inhibitor on cell growth.
Supplementary Table 3 from RON Receptor Tyrosine Kinase as a Therapeutic Target for Eradication of Triple-Negative Breast Cancer: Efficacy of Anti-RON ADC Zt/g4-MMAE
Authors: Suthe Sreedhar Reddy , Yao Hang-Ping , Weng Tian-Hao , Hu Chen-Yu , Feng Liang , Wu Zhi-Gang , Wang Ming-Hai
Published: April 2023

Table S3 is about the sensitivity of TNBC stem-like cells to a different chemotherapeutics.
Figure S3 from Death by HDAC Inhibition in Synovial Sarcoma Cells
Authors: Laporte Aimée N. , Poulin Neal M. , Barrott Jared J. , Wang Xiu Qing , Lorzadeh Alireza , Vander Werff Ryan , Jones Kevin B. , Underhill T. Michael , Nielsen Torsten O.
Published: April 2023

Supplementary Figure S3
Figure S2 from Death by HDAC Inhibition in Synovial Sarcoma Cells
Authors: Laporte Aimée N. , Poulin Neal M. , Barrott Jared J. , Wang Xiu Qing , Lorzadeh Alireza , Vander Werff Ryan , Jones Kevin B. , Underhill T. Michael , Nielsen Torsten O.
Published: April 2023

Supplementary Figure S2
Supplementary Figure 4 from RON Receptor Tyrosine Kinase as a Therapeutic Target for Eradication of Triple-Negative Breast Cancer: Efficacy of Anti-RON ADC Zt/g4-MMAE
Authors: Suthe Sreedhar Reddy , Yao Hang-Ping , Weng Tian-Hao , Hu Chen-Yu , Feng Liang , Wu Zhi-Gang , Wang Ming-Hai
Published: April 2023

Fig. S4 is about the verification of cell surface markers in isolated TNBC stem-like cells.
Figures S1-S7 merged from An Infrared Dye–Conjugated Virus-like Particle for the Treatment of Primary Uveal Melanoma
Authors: Kines Rhonda C. , Varsavsky Isabella , Choudhary Sanghamitra , Bhattacharya Debaditya , Spring Sean , McLaughlin Roger , Kang Shin J. , Grossniklaus Hans E. , Vavvas Demetrios , Monks Stephen , MacDougall John R. , de los Pinos Elisabet , Schiller John T.
Published: April 2023

Figure S1-video composites of real time AU-011 mediated killing of 92.1MEL cells; Figure S2-Killing and binding comparison of free IR700 dye to VLP conjugated IR700 (AU-011) on HeLa and 92.1MEL cells; Figure S3-Demonstration of both the AU-011 dose and light fluence required for AU-011 killing activity on HeLa and 92.1 cells; Figure S4-Examples of the AU-011 EC50 binding and killing curves using 8 tumor cell lines and contributing to values supplied in Table 1; Figure S5-Example of the flow cytometry gating strategy used to obtain the values plotted in the mixed cell experiment shown in Figure 2; Figure S6-Companion confocal images showing time course uptake of AU-011 in 92.1MEL tumors implanted in the eyes of rabbits and quantified in Figure 4; Figure S7-H&E staining of 92.1MEL tumors implanted in rabbit eyes showing dose response effect of AU-011 8-9 days post-treatment.
Table S1 and Figure S1 from Oleanolic Acid Inhibits Epithelial–Mesenchymal Transition of Hepatocellular Carcinoma by Promoting iNOS Dimerization
Authors: Wang Hongzhi , Zhong Weilong , Zhao Jianmin , Zhang Heng , Zhang Qiang , Liang Yuan , Chen Shuang , Liu Huijuan , Zong Shumin , Tian Yixuan , Zhou Honggang , Sun Tao , Liu Yanrong , Yang Cheng
Published: April 2023

Table S1 shows the nitrified proteins identified by mass spectrometry. Figure S1 shows the cytotoxicity assay of OA in HepG2, PLC and SMMC7721 cell lines.
Supplementary Tables 1-3 from Combined Inhibition of PI3Kβ and mTOR Inhibits Growth of PTEN-null Tumors
Authors: Lynch James T. , Polanska Urszula M. , Hancox Ursula , Delpuech Oona , Maynard Juliana , Trigwell Catherine , Eberlein Catherine , Lenaghan Carol , Polanski Radoslaw , Avivar-Valderas Alvaro , Cumberbatch Marie , Klinowska Teresa , Critchlow Susan E. , Cruzalegui Francisco , Barry Simon T.
Published: April 2023

Supplementary Table 1: Cell lines; Supplementary Table 2: Antibodies; Supplementary Table 3: Gene lists
Supplementary Data from Utility of the RIG-I Agonist Triphosphate RNA for Melanoma Therapy
Authors: Helms Mike W. , Jahn-Hofmann Kerstin , Gnerlich Felix , Metz-Weidmann Christiane , Braun Monika , Dietert Gabriele , Scherer Petra , Grandien Kaj , Theilhaber Joachim , Cao Hui , Wagenaar Timothy R. , Schnurr Max M. , Endres Stefan , Wiederschain Dmitri , Scheidler Sabine , Rothenfußer Simon , Brunner Bodo , König Lars M.
Published: April 2023

Supplementary Figure S1 shows that RIG-I, MDA and IRF7 mRNA expression are correlated to the Type I IFN signature in melanoma, while MAVS, TBK1 and IRF3 are not. Supplementary Figure S2 shows a list of gene products correlated with RIG-I expression based on TCGA RNAseq data from 384 melanomas. Ranking is done based on Person correlation coefficients. Supplementary Figure S3 shows a graphical illustration of RIG-I and CXCL-10 expression correlation based on TCGA RNAseq data of melanoma samples. Supplementary Figure S4 shows the results of the analysis of mRNA expression of IFN-β, RIG-I and IP-10 following RNA treatment of C8161 parental cells and CRISPR/Cas generated KO clones. Cells were treated with RIG-I agonist ppp-RNA and respective controls at 100nM. Relative mRNA levels were determined by RT-qPCR 48 hours post treatment by reverse transfection with synthetic ppp-RNA and respective OH-RNA controls as indicated. RIG-I knockout variants are characterized by absence of RIG-I agonist triggered mRNA upregulation secretion. Error bars represent standard deviation. Supplementary Figure S5 shows the flow cytometry analysis of surface antigen expression following ppp-RNA treatment of parental and KO variants of C8161 (a-c) and B16-F10 (d-f). Cells were treated with ppp-RNA and respective controls as indicated at 100nM and analyzed 48 hours post treatment. Supplementary Figure S6 shows IP 10 quantification results of C57BL/6 female mice (n=4 per group), carrying Hepa1-6 liver tumors treated with 50ug RNA complexed with In vivo Jet-PEI (i.v.). Serum was collected for IP-10 quantification 4h post RNA delivery. Error bars indicate standard deviation. Supplementary Figure S7 shows the serum cytokine response profiles 6 hours post first intratumoral treatment with RNA as indicated. Error bars reflect standard deviation. Supplementary Figure S8 shows flow cytometry based analysis of immune cell populations isolated from spleens of B16-F10 tumor bearing mice treated intratumorally with ppp-RNA or respective controls. Spleens were harvested 48h after last treatment. Error bars indicate standard deviation. Supplementary Figure S9 shows the serum cytokine response profile 6 hours post first intratumoral treatment with RNA as indicated. Error bars represent standard deviation. Supplementary Table S1 shows a list of genes comprising the type I IFN signature Supplementary Table S2 shows the results of a Pearson Correlation analysis of OVA-specific CTL frequency versus cytokine expression in the respective animals
Figure S7 from Exploiting Arginine Auxotrophy with Pegylated Arginine Deiminase (ADI-PEG20) to Sensitize Pancreatic Cancer to Radiotherapy via Metabolic Dysregulation
Authors: Singh Pankaj K. , Deorukhkar Amit A. , Venkatesulu Bhanu P. , Li Xiaolin , Tailor Ramesh , Bomalaski John S. , Krishnan Sunil
Published: April 2023

Cell cycle
Fig S1 from Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers
Authors: Hao Huai-Xiang , Wang Hongyun , Liu Chen , Kovats Steven , Velazquez Roberto , Lu Hengyu , Pant Bhavesh , Shirley Matthew , Meyer Matthew J. , Pu Minying , Lim Joanne , Fleming Michael , Alexander LeighAnn , Farsidjani Ali , LaMarche Matthew J. , Moody Susan , Silver Serena J. , Caponigro Giordano , Stuart Darrin D. , Abrams Tinya J. , Hammerman Peter S. , Williams Juliet , Engelman Jeffrey A. , Goldoni Silvia , Mohseni Morvarid
Published: April 2023

(A) Effects of SHP099 and erlotinib on proliferation of EGFR-dependent and RAS/RAF wildtype Detroit-562 and KYSE520 cells grown in 2D monolayer or 3D spheroids (with 20% matrigel) for 6 days. The colored dotted lines at the bottom of graphs are the percentage of Day 0 reading of DMSO-treated cells normalized to that of Day 6 in 2D and 3D, respectively. The black hyphenated lines visualize IC50 values. Error bars denote standard error of the mean. (B-C) Immunoblot of indicated proteins in T3M-4 cells treated with DMSO, SHP099 (10 µM), or trametinib (10 nM) for 2 hours in 2D and 3D culture, respectively. Tubulin serves as a protein loading control. (D) Heatmap depicts Log2 fold change of genes differentially regulated in 2D and 3D following 19 hours after treatment with SHP099. Duplicate samples were analyzed and are depicted. GO ontology was performed using DAVID (42,43) derived from genes with 2-fold change relative to DMSO control.
Supplementary Figure S2 from Predictive and Pharmacodynamic Biomarkers of Response to the Phosphatidylinositol 3-Kinase Inhibitor Taselisib in Breast Cancer Preclinical Models
Authors: Moore Heather M. , Savage Heidi M. , O'Brien Carol , Zhou Wei , Sokol Ethan S. , Goldberg Michael E. , Metcalfe Ciara , Friedman Lori S. , Lackner Mark R. , Wilson Timothy R.
Published: April 2023

Supplementary Figure S2: The in vitro effects of taselisib, lapatinib and trastuzumab in HER2+ breast cancer cell lines.
Supplemental Fig. S5 from Specific CP110 Phosphorylation Sites Mediate Anaphase Catastrophe after CDK2 Inhibition: Evidence for Cooperation with USP33 Knockdown
Authors: Hu Shanhu , Lu Yun , Orr Bernardo , Godek Kristina , Mustachio Lisa Maria , Kawakami Masanori , Sekula David , Compton Duane A. , Freemantle Sarah , Dmitrovsky Ethan
Published: April 2023

Effects of USP33 knock-down on growth inhibition induced by CDK2 antagonism in human lung cancer cells. (A) A549 and (B) Hop62 cells were independently transfected with each of two different USP33 targeting siRNAs or control siRNA. Twenty-four hours after USP33 knock-down, cells were treated with seliciclib (10 μM) for 72 hours and proliferation was measured. The symbols indicate * P < 0.05 and ** P < 0.01.
Supplemental Fig. S4 from Specific CP110 Phosphorylation Sites Mediate Anaphase Catastrophe after CDK2 Inhibition: Evidence for Cooperation with USP33 Knockdown
Authors: Hu Shanhu , Lu Yun , Orr Bernardo , Godek Kristina , Mustachio Lisa Maria , Kawakami Masanori , Sekula David , Compton Duane A. , Freemantle Sarah , Dmitrovsky Ethan
Published: April 2023

Knock-down of Usp33 in murine lung cancer cells does not affect CP110 protein expression. Effects of Usp33 knock-down at 24,48, 72 and 96 hours on CP110 expression in ED-1 cells.
Supplemental Fig. S3 from Specific CP110 Phosphorylation Sites Mediate Anaphase Catastrophe after CDK2 Inhibition: Evidence for Cooperation with USP33 Knockdown
Authors: Hu Shanhu , Lu Yun , Orr Bernardo , Godek Kristina , Mustachio Lisa Maria , Kawakami Masanori , Sekula David , Compton Duane A. , Freemantle Sarah , Dmitrovsky Ethan
Published: April 2023

Effects of CP110 phosphorylation sites on CP110 protein stability. KRAS wild-type ED-1 cells were transfected with CP110-WT or CP110-MUT 24 hours before treatment with or without cycloheximide (CHX, 40μg/ml) for indicated time periods. Expression of CP110 in each time point was shown by immunoblot analyses and ImageJ quantifications.
Supplemental Fig. S1 from Specific CP110 Phosphorylation Sites Mediate Anaphase Catastrophe after CDK2 Inhibition: Evidence for Cooperation with USP33 Knockdown
Authors: Hu Shanhu , Lu Yun , Orr Bernardo , Godek Kristina , Mustachio Lisa Maria , Kawakami Masanori , Sekula David , Compton Duane A. , Freemantle Sarah , Dmitrovsky Ethan
Published: April 2023

Ser 551 and Ser 906 of CP110 are not critical for protecting cells from undergoing anaphase catastrophe. (A) ED-1 cells overexpressing wild-type CP110 (CP110-WT), 8 CDK phosphorylation sites mutated CP110 (CP110-MUT), 10 CDK phosphorylation sites mutated CP110 (CP110-ALL MUT) or an empty vector were treated with the indicated dosage of seliciclib. After 24 hours treatment, ED-1 cells were fixed and scored for multipolar anaphases (NS, not significant). (B) Schematic of CP110-WT, CP110-MUT (8 sites) and CP110-ALL MUT (10 sites) sequences.
Supplementary Table 1 and Supplementary Figures 1-7 from LCL161, a SMAC-mimetic, Preferentially Radiosensitizes Human Papillomavirus–negative Head and Neck Squamous Cell Carcinoma
Authors: Yang Linlin , Kumar Bhavna , Shen Changxian , Zhao Songzhu , Blakaj Dukagjin , Li Tianyun , Romito Mitchell , Teknos Theodoros N. , Williams Terence M.
Published: April 2023

Supplementary Table S1. Characteristics of study population (n=84). Supplementary Figure S1. Validation of cIAP1 antibody by immunohistochemistry. Supplementary Figure S2. Sensitivity of HNSCC cells to radiation or LCL161 as a single agent. Supplementary Figure S3. LCL161 does not alter the phosphorylation of STAT3, AKT and ERK in HNSCC cells. Supplementary Figure S4. Altered treatment schedule of LCL161 and radiation does not affect the radiosensitivity of Cal27 cells. Supplementary Figure S5. LCL161 and radiation do not substantially increase tumor cell expression of TNFα(after 24-48 hrs) but does increase TNFα secretion, and TNFα potentiates radiation mediated-apoptosis in tumor cells. Supplementary Figure S6. Kaplan-Meier survival curves demonstrating percent of mice free from tumor doubling are shown for both Cal27 and FaDu xenografts.α
Supplemental Figures from IQGAP1 Scaffold–MAP Kinase Interactions Enhance Multiple Myeloma Clonogenic Growth and Self-Renewal
Authors: Gocke Christian B. , McMillan Ross , Wang Qiuju , Begum Asma , Penchev Vesselin R. , Ali Syed A. , Borrello Ivan , Huff Carol Ann , Matsui William
Published: April 2023

Supplemental Figure 1. IQGAP1 levels correlate with disease progression and a poor prognosis;Supplemental Figure 2. IQGAP1 levels correlate with RAS pathway activation gene sets;Supplemental Figure 3. The impact of IQGAP1 WW peptide on cell cycle is reversible.
Supplementary methods from AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules
Authors: Guichard Sylvie M. , Curwen Jon , Bihani Teeru , D'Cruz Celina M. , Yates James W.T. , Grondine Michael , Howard Zoe , Davies Barry R. , Bigley Graham , Klinowska Teresa , Pike Kurt G. , Pass Martin , Chresta Christine M. , Polanska Urszula M. , McEwen Robert , Delpuech Oona , Green Stephen , Cosulich Sabina C.
Published: April 2023

Supplementary data on cell lines
Supplementary figure 4 from AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules
Authors: Guichard Sylvie M. , Curwen Jon , Bihani Teeru , D'Cruz Celina M. , Yates James W.T. , Grondine Michael , Howard Zoe , Davies Barry R. , Bigley Graham , Klinowska Teresa , Pike Kurt G. , Pass Martin , Chresta Christine M. , Polanska Urszula M. , McEwen Robert , Delpuech Oona , Green Stephen , Cosulich Sabina C.
Published: April 2023

Gene expression changes in response to AZD2014, fulvestrant and the combination.
Supplementary Methods and Figures S1-S2 from Intratumoral Delivery of an Adenoviral Vector Carrying the SOCS-1 Gene Enhances T-Cell–Mediated Antitumor Immunity By Suppressing PD-L1
Authors: Nakagawa Satoshi , Serada Satoshi , Kakubari Reisa , Hiramatsu Kosuke , Sugase Takahito , Matsuzaki Shinya , Matsuzaki Satoko , Ueda Yutaka , Yoshino Kiyoshi , Ohkawara Tomoharu , Fujimoto Minoru , Kishimoto Tadamitsu , Kimura Tadashi , Naka Tetsuji
Published: April 2023

Figure S1. Stable expression of SOCS-1 suppressed IFN-γ-induced expression of PD-L1 in vitro and tumor growth in vivo; Figure S2. AdSOCS-1 directly inhibits tumor growth of ovarian cancer cell lines in vitro.
Supplementary figure 1 from AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules
Authors: Guichard Sylvie M. , Curwen Jon , Bihani Teeru , D'Cruz Celina M. , Yates James W.T. , Grondine Michael , Howard Zoe , Davies Barry R. , Bigley Graham , Klinowska Teresa , Pike Kurt G. , Pass Martin , Chresta Christine M. , Polanska Urszula M. , McEwen Robert , Delpuech Oona , Green Stephen , Cosulich Sabina C.
Published: April 2023

HCC1428-eveR and HCC1428-LTED-eveR cell lines resistant to everolimus remain sensitive to dual mTORC1/2 inhibitor AZD2014.
Figure S6 from Dual Targeting of ERBB2/ERBB3 for the Treatment of SLC3A2-NRG1–Mediated Lung Cancer
Authors: Shin Dong Hoon , Jo Jeong Yeon , Han Ji-Youn
Published: April 2023

Human normal lung cells, BEAS-2B and CCD18-Lu were transfected with E.V. and Flag S-N gene (3 ï�­g/ï�­l) 2 times per week for 2 weeks and then compared morphologic changes between E.V. and SLC3A2-NRG1 fusion gene and plasmid expression evaluated by Western blots. HEK 293T cells transfected with E.V. and Flag S-N gene. BEAS-2B and CCD18-Lu cells were seeded with 0.4% top agar and cultured with conditioned medium from HEK 293T cells and fresh medium for 40 days. Cell colonies were visualized using crystal violet and counted per 3.8 cm2. The Student''s t test, average {plus minus} SD; n=4, *, p<0.05.
Supplementary Tables 1-3 from Neutralization of BCL-2/XL Enhances the Cytotoxicity of T-DM1 In Vivo
Authors: Zoeller Jason J. , Vagodny Aleksandr , Taneja Krishan , Tan Benjamin Y. , O'Brien Neil , Slamon Dennis J. , Sampath Deepak , Leverson Joel D. , Bronson Roderick T. , Dillon Deborah A. , Brugge Joan S.
Published: April 2023

Supplementary Table 1. Tumor IHC marker specifics; Supplementary Table 2. p-values for Figure 4 comparisons; Supplementary Table 3. p-values for Figure 5 comparisons
Supplementary Figure 7 from Neutralization of BCL-2/XL Enhances the Cytotoxicity of T-DM1 In Vivo
Authors: Zoeller Jason J. , Vagodny Aleksandr , Taneja Krishan , Tan Benjamin Y. , O'Brien Neil , Slamon Dennis J. , Sampath Deepak , Leverson Joel D. , Bronson Roderick T. , Dillon Deborah A. , Brugge Joan S.
Published: April 2023

HER2 levels post-treatment.
Supplemental Table S1 from Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer
Authors: Whalen Kerry A. , White Brian H. , Quinn James M. , Kriksciukaite Kristina , Alargova Rossitza , Au Yeung Tsun P. , Bazinet Patrick , Brockman Adam , DuPont Michelle M. , Oller Haley , Gifford James , Lemelin Charles-Andre , Lim Soo Patrick , Perino Samantha , Moreau Benoît , Sharma Gitanjali , Shinde Rajesh , Sweryda-Krawiec Beata , Bilodeau Mark T. , Wooster Richard
Published: April 2023

Immunohistochemical Analysis of SSTR2 Expression in 44 Small Cell Lung Cancer Patient Samples
Supplementary Figure 2 from Neutralization of BCL-2/XL Enhances the Cytotoxicity of T-DM1 In Vivo
Authors: Zoeller Jason J. , Vagodny Aleksandr , Taneja Krishan , Tan Benjamin Y. , O'Brien Neil , Slamon Dennis J. , Sampath Deepak , Leverson Joel D. , Bronson Roderick T. , Dillon Deborah A. , Brugge Joan S.
Published: April 2023

Comparison of continuous versus pulsatile combination treatments.
Supplemental Figure S3 from Targeting the Somatostatin Receptor 2 with the Miniaturized Drug Conjugate, PEN-221: A Potent and Novel Therapeutic for the Treatment of Small Cell Lung Cancer
Authors: Whalen Kerry A. , White Brian H. , Quinn James M. , Kriksciukaite Kristina , Alargova Rossitza , Au Yeung Tsun P. , Bazinet Patrick , Brockman Adam , DuPont Michelle M. , Oller Haley , Gifford James , Lemelin Charles-Andre , Lim Soo Patrick , Perino Samantha , Moreau Benoît , Sharma Gitanjali , Shinde Rajesh , Sweryda-Krawiec Beata , Bilodeau Mark T. , Wooster Richard
Published: April 2023

Pharmacokinetic analysis of PEN-221 and DM1 in non-tumor bearing mice
Supplementary Figure 1 from Neutralization of BCL-2/XL Enhances the Cytotoxicity of T-DM1 In Vivo
Authors: Zoeller Jason J. , Vagodny Aleksandr , Taneja Krishan , Tan Benjamin Y. , O'Brien Neil , Slamon Dennis J. , Sampath Deepak , Leverson Joel D. , Bronson Roderick T. , Dillon Deborah A. , Brugge Joan S.
Published: April 2023

Assessment of ERBB2 amplification.
Supplemental Figure 7 from Short- and Long-Term Effects of CDK4/6 Inhibition on Early-Stage Breast Cancer
Authors: Kietzman William B. , Graham Garrett T. , Ory Virginie , Sharif Ghada M. , Kushner Max H. , Gallanis Gregory T. , Kallakury Bhaskar , Wellstein Anton , Riegel Anna T.
Published: April 2023

Palbociclib's stromal impact and cancer outcomes
Supplementary Video Legend from Targeting Mitochondrial Proline Dehydrogenase with a Suicide Inhibitor to Exploit Synthetic Lethal Interactions with p53 Upregulation and Glutaminase Inhibition
Authors: Scott Gary K. , Yau Christina , Becker Beatrice C. , Khateeb Sana , Mahoney Sophia , Jensen Martin Borch , Hann Byron , Cowen Bryan J. , Pegan Scott D. , Benz Christopher C.
Published: April 2023

Legend for Supplementary videos S1A and S1B
Supplemental Figure 2 from Short- and Long-Term Effects of CDK4/6 Inhibition on Early-Stage Breast Cancer
Authors: Kietzman William B. , Graham Garrett T. , Ory Virginie , Sharif Ghada M. , Kushner Max H. , Gallanis Gregory T. , Kallakury Bhaskar , Wellstein Anton , Riegel Anna T.
Published: April 2023

Palbociclib treated 3D time course
Movie S6 from Macrophage-Mediated Trogocytosis Leads to Death of Antibody-Opsonized Tumor Cells
Authors: Velmurugan Ramraj , Challa Dilip K. , Ram Sripad , Ober Raimund J. , Ward E. Sally
Published: April 2023

MUM images of trogocytic tubules.The movie corresponds to Figure 4B. Images of trastuzumab (left panels) or trastuzumab and MEM-GFP (red and green, respectively; right panels) from the cameras set at focal planes of ~ 1.2 Âµm and 1.8 Âµm in the MUM configuration are displayed. The cyan line in the left panels indicates the approximate edge of the macrophage, obtained by averaging and thresholding the MEM-GFP images. The movie pauses for 2 seconds at different timepoints to indicate the same features of the tubulation process (yellow arrows) presented as individual frames in Figure 4B. Time on the upper left is shown in minutes:seconds format. The movie plays at a speed of 27x real-time. Scale bar = 5 Âµm.
Movie S5 from Macrophage-Mediated Trogocytosis Leads to Death of Antibody-Opsonized Tumor Cells
Authors: Velmurugan Ramraj , Challa Dilip K. , Ram Sripad , Ober Raimund J. , Ward E. Sally
Published: April 2023

Live cell imaging of macrophage-mediated trogocytosis. The movie shows trastuzumab from live, opsonized MDA-MB-453 cells being trogocytosed by CD45-labeled J774A.1 macrophages. Upper left panel shows signal from Alexa 555-labeled trastuzumab, upper right panel shows CD45 signal, lower left panel shows the transmitted light image and the lower right image shows the overlay of the upper two panels. The sample was imaged in the presence of caspase 3/7 detection reagent for which the signal is also detected in the CD45 channel. The movie plays at a speed of 340x real-time. Scale bar = 5 Âµm.
Movie S4 from Macrophage-Mediated Trogocytosis Leads to Death of Antibody-Opsonized Tumor Cells
Authors: Velmurugan Ramraj , Challa Dilip K. , Ram Sripad , Ober Raimund J. , Ward E. Sally
Published: April 2023

Transmitted-light imaging of an SK-BR-3 cell in a human macrophage co-culture in the presence of trastuzumab. Movie shows the fate of an SK-BR-3 cell as in Movie S2, but with human macrophages as effector cells. Purified human monocytes were plated six days prior to the addition of cancer cells. The title on the panel indicates the time progression in days - hours:minutes format. The movie plays at a speed of 3600x real-time.
Movie S3 from Macrophage-Mediated Trogocytosis Leads to Death of Antibody-Opsonized Tumor Cells
Authors: Velmurugan Ramraj , Challa Dilip K. , Ram Sripad , Ober Raimund J. , Ward E. Sally
Published: April 2023

Transmitted-light imaging of the fate of an SK-BR-3 cell in a RAW264.7:SK-BR-3 co-culture in the presence of trastuzumab. Movie shows the fate of an SK-BR-3 cell as in Movie S2, but with RAW264.7 macrophages as the effector cells. The title on the right panel shows the time in days - hours:minutes format. The movie plays at a speed of 1400x real-time.
Movie S2 from Macrophage-Mediated Trogocytosis Leads to Death of Antibody-Opsonized Tumor Cells
Authors: Velmurugan Ramraj , Challa Dilip K. , Ram Sripad , Ober Raimund J. , Ward E. Sally
Published: April 2023

Transmitted-light imaging of the fate of an SK-BR-3 cell in a J774A.1:SK-BR-3 co-culture in the presence of trastuzumab. The left panel in the movie tracks an SK-BR-3 cell (yellow box) amongst J774A.1 macrophages in the presence of 1 Âµg/ml trastuzumab over 3 days. The right panel traces the absolute displacement of the tracked SK-BR-3 cell in the flask over time. The title on the right panel shows the time (days) and the speed at which the movie is being played (2700x real-time until 00:42 and 900x real-time after 00:42).
Figure S3. Differential expression of MDM2 and PARP1 in B-ALL patient samples. from Antileukemia Effects of Notch-Mediated Inhibition of Oncogenic PLK1 in B-Cell Acute Lymphoblastic Leukemia
Authors: Kannan Sankaranarayanan , Aitken Marisa J.L. , Herbrich Shelley M. , Golfman Leonard S. , Hall Mandy G. , Mak Duncan H. , Burks Jared K. , Song Guangchun , Konopleva Marina , Mullighan Charles G. , Chandra Joya , Zweidler-McKay Patrick A.
Published: April 2023

U133A microarray (Affymetrix) gene expression data for 172 B-ALL patients, 34 T-ALL patients.
Figure S3 from The Role of Pyruvate Dehydrogenase Kinase-4 (PDK4) in Bladder Cancer and Chemoresistance
Authors: Woolbright Benjamin L. , Choudhary Dharamainder , Mikhalyuk Andrew , Trammel Cassandra , Shanmugam Sambantham , Abbott Erika , Pilbeam Carol C. , Taylor John A.
Published: April 2023

Xenograft tumor volume
Figure S1. Notch-induced cell death in B-ALL. from Antileukemia Effects of Notch-Mediated Inhibition of Oncogenic PLK1 in B-Cell Acute Lymphoblastic Leukemia
Authors: Kannan Sankaranarayanan , Aitken Marisa J.L. , Herbrich Shelley M. , Golfman Leonard S. , Hall Mandy G. , Mak Duncan H. , Burks Jared K. , Song Guangchun , Konopleva Marina , Mullighan Charles G. , Chandra Joya , Zweidler-McKay Patrick A.
Published: April 2023

(A) Representative histograms of Annexin V abundance in Ph-like B-ALL patient samples cultured with pate-bound IgG-Fc and and increasing concentrations of DLL1-Fc after 3 days. (B) mRNA expression of Notch target gene HES1 in T-ALL and B-ALL cell lines and patient samples (Pt.B1, Pt.B2) was assessed by real-time qRT-PCR (in triplicate).
Supplementary Figure 1 Legend: Early cutaneous invasion of WM35 melanoma cells in full-thickness human skin equivalents results in disruption of basement membrane component type IV collagen from A Novel Fully Humanized 3D Skin Equivalent to Model Early Melanoma Invasion
Authors: Hill David S. , Robinson Neil D.P. , Caley Matthew P. , Chen Mei , O'Toole Edel A. , Armstrong Jane L. , Przyborski Stefan , Lovat Penny E.
Published: April 2023

legend to supplementary figure 1
Supplementary Figure Legends from Poly-ADP-Ribose Polymerase as a Therapeutic Target in Pediatric Diffuse Intrinsic Pontine Glioma and Pediatric High-Grade Astrocytoma
Authors: Chornenkyy Yevgen , Agnihotri Sameer , Yu Man , Buczkowicz Pawel , Rakopoulos Patricia , Golbourn Brian , Garzia Livia , Siddaway Robert , Leung Stephie , Rutka James T. , Taylor Michael D. , Dirks Peter B. , Hawkins Cynthia
Published: April 2023

Supplementary Figure Legends
Supplementary Figures S1-S3 and Tables S1-S4 from c-Jun N-Terminal Kinase Inactivation by Mitogen-Activated Protein Kinase Phosphatase 1 Determines Resistance to Taxanes and Anthracyclines in Breast Cancer
Authors: Rincón Raúl , Zazo Sandra , Chamizo Cristina , Manso Rebeca , González-Alonso Paula , Martín-Aparicio Ester , Cristóbal Ion , Cañadas Carmen , Perona Rosario , Lluch Ana , Eroles Pilar , García-Foncillas Jesús , Albanell Joan , Rovira Ana , Madoz-Gúrpide Juan , Rojo Federico
Published: April 2023

Supplementary Figure S1. MKP-1 protein abundance levels in MDA-MB-231 cells treated with docetaxel at progressively increasing times. Supplementary Figure S2. Cell growth in the presence of the docetaxel or doxorubicin of breast cancer cell lines overexpressing MKP-1. Supplementary Table S1. Clinical and molecular characteristics of a series of 350 patients with early breast cancer. Supplementary Figure S3. IHC detection of MKP-1 and p-JNK1/2 in a representative normal tissue sample. Supplementary Table S2. Univariate and multivariate Cox analyses in the cohort of 350 breast cancer patients (disease-free survival analysis). Supplementary Table S3. Clinical and molecular characteristics of 64 locally advanced breast cancer patients who received neoadjuvant taxane-based chemotherapy.Supplementary Table S4. MKP-1 and p-JNK1/2 marker determinations in locally advanced breast cancer patients who received neoadjuvant taxane-based chemotherapy.
Supplementary Table 2 from Antitumor Activity and Acquired Resistance Mechanism of Dovitinib (TKI258) in RET-Rearranged Lung Adenocarcinoma
Authors: Kang Chan Woo , Jang Kang Won , Sohn Jinyoung , Kim Sung-Moo , Pyo Kyoung-Ho , Kim Hwan , Yun Mi Ran , Kang Han Na , Kim Hye Ryun , Lim Sun Min , Moon Yong Wha , Paik Soonmyung , Kim Dae Joon , Kim Joo Hang , Cho Byoung Chul
Published: April 2023

Supplementary Table 2. siRNA sequences
Supplementary Figure 3A from Antitumor Activity and Acquired Resistance Mechanism of Dovitinib (TKI258) in RET-Rearranged Lung Adenocarcinoma
Authors: Kang Chan Woo , Jang Kang Won , Sohn Jinyoung , Kim Sung-Moo , Pyo Kyoung-Ho , Kim Hwan , Yun Mi Ran , Kang Han Na , Kim Hye Ryun , Lim Sun Min , Moon Yong Wha , Paik Soonmyung , Kim Dae Joon , Kim Joo Hang , Cho Byoung Chul
Published: April 2023

Supplementary Figure 3A. Inhibition of FAK activity in LC-2/ad cells and LC-2/ad DR cells. A, MTT assays of LC-2/ad and LC-2/ad DR cells. Cells were treated with indicated dose of dovitinib, PF-52,271, or both for 72hr, and cell viability was determined using MTT. Means are derived from three replicate (n=3). Error bars indicate mean {plus minus} SE of three replicates.
Table S1 from LncRNA CCAT1 Promotes Prostate Cancer Cell Proliferation by Interacting with DDX5 and MIR-28-5P
Authors: You Zonghao , Liu Chunhui , Wang Can , Ling Zhixin , Wang Yiduo , Wang Yali , Zhang Minghao , Chen Shuqiu , Xu Bin , Guan Han , Chen Ming
Published: April 2023

The list of miRNA mimics, miRNA inhibitors, primers and shRNA sequence.
AC0010 supplementary Figure 3 from AC0010, an Irreversible EGFR Inhibitor Selectively Targeting Mutated EGFR and Overcoming T790M-Induced Resistance in Animal Models and Lung Cancer Patients
Authors: Xu Xiao , Mao Long , Xu Wanhong , Tang Wei , Zhang Xiaoying , Xi Biao , Xu Rongda , Fang Xin , Liu Jia , Fang Ce , Zhao Li , Wang Xiaobo , Jiang Ji , Hu Pei , Zhao Hongyun , Zhang Li
Published: April 2023

AC0010 Supplementary Figure 3. Impact of AC0010 and gefitinib administration on tumor volumes
Figure S4 from LncRNA CCAT1 Promotes Prostate Cancer Cell Proliferation by Interacting with DDX5 and MIR-28-5P
Authors: You Zonghao , Liu Chunhui , Wang Can , Ling Zhixin , Wang Yiduo , Wang Yali , Zhang Minghao , Chen Shuqiu , Xu Bin , Guan Han , Chen Ming
Published: April 2023

Pulldown assays showed miR-125a-3p and miR-125b-5p interacted with CCAT1,CCK8 assays showed that miR-125a-3p and miR-125b-5p manifested anti-cancer effect in Du145 cells
AC0010 supplementary Figure 1 from AC0010, an Irreversible EGFR Inhibitor Selectively Targeting Mutated EGFR and Overcoming T790M-Induced Resistance in Animal Models and Lung Cancer Patients
Authors: Xu Xiao , Mao Long , Xu Wanhong , Tang Wei , Zhang Xiaoying , Xi Biao , Xu Rongda , Fang Xin , Liu Jia , Fang Ce , Zhao Li , Wang Xiaobo , Jiang Ji , Hu Pei , Zhao Hongyun , Zhang Li
Published: April 2023

AC0010 Supplementary Figure 1. AC0010 covalently binds to cysteine 797 in EGFR T790M
Supplementary Figure S7 from Acquired Resistance to BET-PROTACs (Proteolysis-Targeting Chimeras) Caused by Genomic Alterations in Core Components of E3 Ligase Complexes
Authors: Zhang Lu , Riley-Gillis Bridget , Vijay Priyanka , Shen Yu
Published: April 2023

Mutational signature analysis.
Supplementary Figure S2 from Acquired Resistance to BET-PROTACs (Proteolysis-Targeting Chimeras) Caused by Genomic Alterations in Core Components of E3 Ligase Complexes
Authors: Zhang Lu , Riley-Gillis Bridget , Vijay Priyanka , Shen Yu
Published: April 2023

Sensitivity and apoptotic response to BET PROTACs in SKM1, MV4:11, LNCaP and OVCAR8 cells.
Supplemental Tables 1-2 from Acquired Resistance to BET-PROTACs (Proteolysis-Targeting Chimeras) Caused by Genomic Alterations in Core Components of E3 Ligase Complexes
Authors: Zhang Lu , Riley-Gillis Bridget , Vijay Priyanka , Shen Yu
Published: April 2023

Supplemental Table 1: TaqMan CNV assays; Supplemental Table 2:Sanger PCR primers
Supplementary Table S1 from E7090, a Novel Selective Inhibitor of Fibroblast Growth Factor Receptors, Displays Potent Antitumor Activity and Prolongs Survival in Preclinical Models
Authors: Watanabe Miyano Saori , Yamamoto Yuji , Kodama Kotaro , Miyajima Yukiko , Mikamoto Masaki , Nakagawa Takayuki , Kuramochi Hiroko , Funasaka Setsuo , Nagao Satoshi , Sugi Naoko Hata , Okamoto Kiyoshi , Minoshima Yukinori , Nakatani Yusuke , Karoji Yuki , Ohashi Isao , Yamane Yoshinobu , Okada Toshimi , Matsushima Tomohiro , Matsui Junji , Iwata Masao , Uenaka Toshimitsu , Tsuruoka Akihiko
Published: April 2023

IC50 values for the inhibition of 93 human kinases by E7090.
Supplementary Figure S1 from Establishment and Characterization of Histologically and Molecularly Stable Soft-tissue Sarcoma Xenograft Models for Biological Studies and Preclinical Drug Testing
Authors: Cornillie Jasmien , Wozniak Agnieszka , Li Haifu , Wang Yannick , Boeckx Bram , Gebreyohannes Yemarshet K. , Wellens Jasmien , Vanleeuw Ulla , Hompes Daphne , Stas Marguerite , Sinnaeve Friedl , Wafa Hazem , Lambrechts Diether , Debiec-Rychter Maria , Sciot Raf , Schöffski Patrick
Published: April 2023

Genomic profile, describing copy number gains and losses, obtained using low coverage whole genome sequencing of subsequent passages of STS PDX models, revealing a stable copy number profile throughout passaging. Copy number profile of (A) the MPNST model UZLX-STS39 and (B) the mesenchymal chondrosarcoma model UZLX-STS41.
Supplementary Figure 3 from SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors
Authors: Lu Hengyu , Liu Chen , Velazquez Roberto , Wang Hongyun , Dunkl Lukas Manuel , Kazic-Legueux Malika , Haberkorn Anne , Billy Eric , Manchado Eusebio , Brachmann Saskia M. , Moody Susan E. , Engelman Jeffrey A. , Hammerman Peter S. , Caponigro Giordano , Mohseni Morvarid , Hao Huai-Xiang
Published: April 2023

Evaluation of the in vitro synergy in anti-proliferation and the MAPK pathway suppression of MEK and SHP2, PI3K, or RTK inhibitors.
Supplementary Figure 7 - In vitro characterization of F8-mIFNa2 and therapy study with either F8-mIFNa2, Doxorubicin or the combination in BALB/c mice bearing WEHI-164 sarcoma. from Antibody-Based Delivery of Cytokine Payloads to Carbonic Anhydrase IX Leads to Cancer Cures in Immunocompetent Tumor-Bearing Mice
Authors: Ziffels Barbara , Stringhini Marco , Probst Philipp , Fugmann Tim , Sturm Theo , Neri Dario
Published: April 2023

a) cloning scheme. b) expected protein structure, yield of TGE in CHO-S cells and expected molecular weight. c) SDS-PAGE analysis (kDa: marker in kDa, nr: non-reduced, r: reduced). d) Size exclusion profile and standard proteins indicated by black arrows (1: IgG, 145 kDa, 2: BSA, 67 kDa, 3: Diabody, 25 kDa). e) MS profile. f) BIAcore profile using a human EDA coated CM5 sensor chip. g) Activity assay for the respective payload. h) WEHI-164 sarcoma bearing BALB/c mice received either PBS as control (three injections) or 5 mg/kg Doxorubicin (one injection) or 150 Âµg of F8-mIFNa2 (three injections) or the combination of Doxorubicin and F8-mIFNa2. Statistical significance towards PBS control group is shown on day 14, *p<0.05, **p<0.005, ***p<0.0005. i) Body weight change during the treatment phase.
Supplementary Table 3 from Analysis of the Genomic Landscape in ALK+ NSCLC Patients Identifies Novel Aberrations Associated with Clinical Outcomes
Authors: Couëtoux du Tertre Mathilde , Marques Maud , Tremblay Lise , Bouchard Nicole , Diaconescu Razvan , Blais Normand , Couture Christian , Pelsser Vincent , Wang Hangjun , Higenell Valerie , Izzi Luisa , Gambaro Karen , Hoffert Cyrla , Srivastava Archana , Spatz Alan , Rousseau Caroline , McNamara Suzan , Cohen Victor , Batist Gerald , Agulnik Jason
Published: April 2023

Summary of the number of events by patient.
Supplementary Table S1 from Enhancing Therapeutic Efficacy of Oncolytic Herpes Simplex Virus-1 with Integrin β1 Blocking Antibody OS2966
Authors: Lee Tae Jin , Nair Mitra , Banasavadi-Siddegowda Yeshavanth , Liu Joseph , Nallanagulagari Tejaswini , Jaime-Ramirez Alena Cristina , Guo Jeffrey Yunhua , Quadri Haroon , Zhang Jianying , Bockhorst Kurt H. , Aghi Manish K. , Carbonell W. Shawn , Kaur Balveen , Yoo Ji Young
Published: April 2023

Supplementary Table S1 shows sequences of primers used in this study.
Supplementary Figure S3 from Enhancing Therapeutic Efficacy of Oncolytic Herpes Simplex Virus-1 with Integrin β1 Blocking Antibody OS2966
Authors: Lee Tae Jin , Nair Mitra , Banasavadi-Siddegowda Yeshavanth , Liu Joseph , Nallanagulagari Tejaswini , Jaime-Ramirez Alena Cristina , Guo Jeffrey Yunhua , Quadri Haroon , Zhang Jianying , Bockhorst Kurt H. , Aghi Manish K. , Carbonell W. Shawn , Kaur Balveen , Yoo Ji Young
Published: April 2023

Supplementary Figure S3 shows that Combination treatment with OS2966 and oHSV does not enhance mice survival rate in intracranial glioma-bearing mice in vivo.
Supplemental Methods; Supplemental Tables 1 and 2 from Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience
Authors: Schwaederle Maria , Parker Barbara A. , Schwab Richard B. , Daniels Gregory A. , Piccioni David E. , Kesari Santosh , Helsten Teresa L. , Bazhenova Lyudmila A. , Romero Julio , Fanta Paul T. , Lippman Scott M. , Kurzrock Razelle
Published: April 2023

Supplemental Methods 1) Sequencing: (182 and 236 gene lists) 2)Therapy 3) Matching Score 4) Statistical Analysis (patient's characteristics, study endpoints and definitions, analyses performed);Supplemental Table 1. Patient characteristics; Supplemental Table 2. List of alterations and matched drugs; Supplemental Figure 1. Overall survival analysis
Supplemental Methods from Regulation of HIF1α under Hypoxia by APE1/Ref-1 Impacts CA9 Expression: Dual Targeting in Patient-Derived 3D Pancreatic Cancer Models
Authors: Logsdon Derek P. , Grimard Michelle , Luo Meihua , Shahda Safi , Jiang Yanlin , Tong Yan , Yu Zhangsheng , Zyromski Nicholas , Schipani Ernestina , Carta Fabrizio , Supuran Claudiu T. , Korc Murray , Ivan Mircea , Kelley Mark R. , Fishel Melissa L.
Published: April 2023

Additional methods including synthesis information for one of the inhibitors used and methods used for TCGA survival analysis found in supplemental figure 7.
Supplementary Figure S2 from A Kinase Inhibitor with Anti-Pim Kinase Activity is a Potent and Selective Cytotoxic Agent Toward Acute Myeloid Leukemia
Authors: Bjørnstad Ronja , Aesoy Reidun , Bruserud Øystein , Brenner Annette K. , Giraud Francis , Dowling Tara Helen , Gausdal Gro , Moreau Pascale , Døskeland Stein Ove , Anizon Fabrice , Herfindal Lars
Published: April 2023

Levels of Akt and p70 S6 kinase after treatment with Pim kinase inhibitors